Global Neurometabolic Disorders Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neurometabolic Disorders Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
Neurometabolic Disorders report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Neurometabolic Disorders market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oral and Parenteral are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Neurometabolic Disorders industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Neurometabolic Disorders key companies include Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation and Lixte Biotechnology, etc. Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals are top 3 players and held % share in total in 2022.
Neurometabolic Disorders can be divided into Gaucher’s Disease, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI, etc. Gaucher’s Disease is the mainstream product in the market, accounting for % share globally in 2022.
Neurometabolic Disorders is widely used in various fields, such as Oral and Parenteral, etc. Oral provides greatest supports to the Neurometabolic Disorders industry development. In 2022, global % share of Neurometabolic Disorders went into Oral filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neurometabolic Disorders market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Oral
Parenteral
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Neurometabolic Disorders market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Neurometabolic Disorders introduction, etc. Neurometabolic Disorders Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Neurometabolic Disorders market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Neurometabolic Disorders report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Neurometabolic Disorders market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oral and Parenteral are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Neurometabolic Disorders industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Neurometabolic Disorders key companies include Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation and Lixte Biotechnology, etc. Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals are top 3 players and held % share in total in 2022.
Neurometabolic Disorders can be divided into Gaucher’s Disease, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI, etc. Gaucher’s Disease is the mainstream product in the market, accounting for % share globally in 2022.
Neurometabolic Disorders is widely used in various fields, such as Oral and Parenteral, etc. Oral provides greatest supports to the Neurometabolic Disorders industry development. In 2022, global % share of Neurometabolic Disorders went into Oral filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neurometabolic Disorders market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Segment by Application
Oral
Parenteral
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Neurometabolic Disorders market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Neurometabolic Disorders introduction, etc. Neurometabolic Disorders Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Neurometabolic Disorders market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices